

International Society for Heart and Lung Transplantation (ISHLT) conference 2023!



Close On The Heels Of The Recent FDA Approval Of The Software Upgrades To The Freedom Driver, Team SynCardia Was Out In Force At The Annual Conference Of International Society For Heart And Lung Transplantation (ISHLT).

Denver, CO – April 19th – 22th, 2023 – SynCardia demonstrates prototypes for the upgraded Freedom Hush driver and the new Liberty driver at ISHLT in Denver.

Close On The Heels Of The Recent FDA Approval Of The Software Upgrades To The Freedom Driver, Team SynCardia Was Out In Force At The Annual Conference Of International Society For Heart And Lung Transplantation (ISHLT) In Denver Apr 19-22, 2023.

Among the many updates provided were demonstrations of:

- Software updates available from May 1 that improves “Cardiac Output measurement accuracy”, particularly for the new 50cc implant.
- Prototype Freedom Hush Driver that is expected to be significantly softer than the current Freedom Driver.
- New driver features that may allow physicians to access continuous and real-time readings of a patient’s Right and Left Atrial Pressures (RAP/LAP), the Pulmonary Arterial Pressure (RAP), and Systolic/Diastolic Arterial Pressure in the future.
- Next-gen “Liberty” portable driver that is expected to be at a fraction of the weight and size of the current Freedom Drivers.

The Freedom Hush and Liberty Drivers, as well as the pressure reading features are currently not approved for patient use in the US and in Europe. What were demonstrated are advanced engineering prototypes in varying stages of design control. For more information, please contact info@syncardia.com

In one of the more light-hearted sessions in the conference, ChatGPT concurred with a voting audience of cardiologists and transplant surgeons, that the Total Artificial Heart (TAH) was preferred over a durable LVAD for the treatment of a hypothetical patient with biventricular failure.

Team SynCardia hopes to see everyone again at ASAIO 2023 and HFSA 2023 with further updates on these exciting developments. Stay tuned!



SynCardia Systems, LLC
 1992 E. Silverlake Rd. Tucson, AZ 85713
 +1 520-545-1234 | info@syncardia.com
www.SynCardia.com






#SynCardia

About SynCardia Systems, LLC

Headquartered in Tucson, Ariz., SynCardia manufactures the world's only commercially approved total artificial heart. In clinical use for more than 35 years and with more than 1,800 implants, the SynCardia temporary Total Artificial Heart (TAH) is the most widely used and extensively studied TAH in the world.

By partnering with, training and supporting healthcare teams at more than 140 transplant hospitals and heart failure programs in more than 20 countries, SynCardia helps create better outcomes for critically ill adults and adolescents whose best chance at survival is total heart replacement. When a donor heart isn't an available option, SynCardia provides a new heart without the wait for patients with end-stage heart failure affecting both sides of the heart (biventricular failure).

SynCardia Systems, LLC – a Picard Medical Company

The SynCardia temporary Total Artificial Heart (TAH-t) is a treatment option for cardiac transplant-eligible patients at risk of imminent death from biventricular failure.

Medical Advice Disclaimer

The information, including but not limited to, text, graphics, images and other material contained on this website are for informational purposes only. No material on this site is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or a qualified health care provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of information you have read on this website. © SynCardia Systems, LLC | All rights reserved.